UDCA has, therefore, been evaluated for the treatment of patients with PSC. Trials of UDCA at low doses (10–15 mg/kg per day and 17–20 mg/kg per day) have yielded inconclusive results in ...

Shilpa Medicare announces the approval of its IND - Nor Ursodeoxycholic Acid Tablets 500 mg, by the Subject Expert Committee of CDSCO. The Committee has further recommended grant of marketing ...

The trials identified no serious adverse effects, and patients tolerated a daily dosage of 1500 mg for 24 weeks.

Raichur: Shilpa Medicare Limited, recently announced that its Investigational New Drug (IND), Nor-Ursodeoxycholic Acid ...